Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

被引:41
作者
Zhu, Litao [1 ]
Zhao, Li [1 ]
Wang, Hu [1 ]
Wang, Yu [1 ]
Pan, Di [1 ]
Yao, Jing [1 ]
Li, Zhiyu [3 ]
Wu, Guanzhong [2 ]
Guo, Qinglong [1 ]
机构
[1] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, State Key Lab Nat Med, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China
[3] China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
Oroxylin A; MCF7/ADR; G2/M; P-gp; Chk2; NF-KAPPA-B; DRUG-RESISTANCE; ANTICANCER DRUG; GENE-EXPRESSION; MOLECULAR TARGETS; INDUCED APOPTOSIS; DOWN-REGULATION; CYCLE ARREST; CANCER CELLS; WOGONIN;
D O I
10.1016/j.toxlet.2013.01.019
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Oroxylin A is a naturally occurring monoflavonoid isolated from the root of Scutellaria baicalensis Georgi, which has been used in traditional Chinese medicine for its anti-tumor, anti-inflammatory and antibacterial properties. The purpose of this study is to investigate the reversal effect and the fundamental mechanisms of oroxylin A in MCF7/ADR cells. Data indicated that oroxylin A showed strong reversal potency in MCF7/ADR cells and the reversal fold (RF) reached 4.68. After treatment with oroxylin A, MCF7/ADR cells displayed reduced functional activity and expression of MDR1 at both the protein and mRNA levels. Meanwhile, oroxylin A induced cells G2/M arrest in a concentration-dependent manner by increasing the expression of p-Chk2 (Thr68). Moreover, western blot and EMSA assays were used to reveal the inhibition of NF-kappa B in nucleus and the suppression of NF-kappa B binding activity by oroxylin A. NSC 109555 ditosylate-Chk2 inhibitor partly dismissed G2/M arrest induced by oroxylin A, reversed the increased trend of p-Chk2 and p-P53 (Ser20), inhibited the decreasing effect of oroxylin A on the expression of P-gp and decreased the reversal fold of 90 mu M oroxylin A from 4.68 fold to 1.73 fold. In conclusion, we suggested that oroxylin A reversed MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-kappa B signaling pathway. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:107 / 115
页数:9
相关论文
共 48 条
[1]   Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells [J].
Anuchapreeda, S ;
Leechanachai, P ;
Smith, MM ;
Ambudkar, SV ;
Limtrakul, P .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (04) :573-582
[2]   NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells [J].
Bentires-Alj, M ;
Barbu, V ;
Fillet, M ;
Chariot, A ;
Relic, B ;
Jacobs, N ;
Gielen, J ;
Merville, MP ;
Bours, V .
ONCOGENE, 2003, 22 (01) :90-97
[3]   A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase [J].
Blasina, A ;
Van de Weyer, I ;
Laus, MC ;
Luyten, WHML ;
Parker, AE ;
McGowan, CH .
CURRENT BIOLOGY, 1999, 9 (01) :1-10
[4]   ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY [J].
BLUM, RH ;
CARTER, SK .
ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :249-259
[5]   Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance [J].
Bram, Eran E. ;
Stark, Michal ;
Raz, Shachar ;
Assaraf, Yehuda G. .
NEOPLASIA, 2009, 11 (12) :1359-U133
[6]  
Brooks T, 2003, MOL CANCER THER, V2, P1195
[7]   Cell cycle molecular targets in novel anticancer drug discovery [J].
Buolamwini, JK .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) :379-392
[8]  
Calcagno Anna Maria, 2007, Current Drug Delivery, V4, P324, DOI 10.2174/156720107782151241
[9]   P-GLYCOPROTEIN EXPRESSION AS A PREDICTOR OF THE OUTCOME OF THERAPY FOR NEUROBLASTOMA [J].
CHAN, HSL ;
HADDAD, G ;
THORNER, PS ;
DEBOER, G ;
LIN, YP ;
ONDRUSEK, N ;
YEGER, H ;
LING, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1608-1614
[10]   Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway [J].
Chaturvedi, P ;
Eng, WK ;
Zhu, Y ;
Mattern, MR ;
Mishra, R ;
Hurle, MR ;
Zhang, XL ;
Annan, RS ;
Lu, Q ;
Faucette, LF ;
Scott, GF ;
Li, XT ;
Carr, SA ;
Johnson, RK ;
Winkler, JD ;
Zhou, BBS .
ONCOGENE, 1999, 18 (28) :4047-4054